Summary Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease progression, and monitoring the therapeutic responsiveness of cancers. Immunovia’s IMMray can also be used for biomarker discovery through its discovery tool for proteome scanning. The company also provides IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Its therapeutic areas include cancer and autoimmune diseases such as systemic lupus erythematosus. The company collaborates with various cancer centers for conducting clinical evidence studies. Immunovia is headquartered in Lund, Sweden. Immunovia AB (IMMNOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers... Research Beam Model: Research Beam Product ID: 2619881 250 USD New
Immunovia AB (IMMNOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Immunovia AB (IMMNOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Pharmaceuticals
  • Published On : October   2017
  • Pages : 29
  • Publisher : GlobalData
 
 
 
Summary

Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease progression, and monitoring the therapeutic responsiveness of cancers. Immunovia’s IMMray can also be used for biomarker discovery through its discovery tool for proteome scanning. The company also provides IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Its therapeutic areas include cancer and autoimmune diseases such as systemic lupus erythematosus. The company collaborates with various cancer centers for conducting clinical evidence studies. Immunovia is headquartered in Lund, Sweden.

Immunovia AB (IMMNOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immunovia AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Immunovia AB, Medical Devices Deals, 2011 to YTD 2017 9
Immunovia AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Immunovia AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Immunovia to Enter into Agreement with National Cancer Institute 11
Immunovia Enters into Agreement with University of Liverpool 12
Immunovia Partners with OHSU Knight Cancer Institute 13
Licensing Agreements 14
Alligator Bioscience Enters Into Licensing Agreement With Immunovia For Scala-11 14
Equity Offering 15
Immunovia Raises USD3.4 Million in Rights Offering of Shares 15
Immunovia Prices Private Placement of Shares for USD22.3 Million 17
Immunovia Plans to Raise Funds in Public Offering of Shares 18
Immunovia Raises USD7 Million in IPO 19
Immunovia AB - Key Competitors 20
Immunovia AB - Key Employees 21
Immunovia AB - Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Apr 20, 2017: Immunovia Interim report, January-March 2017 23
Feb 15, 2017: Immunovia Financial Statement 2016 24
Aug 24, 2016: Immunovia: Half-year report 2016 25
Feb 24, 2016: Immunovia Year-end report 2015 26
Corporate Communications 27
Jul 17, 2017: Leading pancreatic cancer expert on early symptoms Professor Stephen Pereira at University College London joins Immunovia’s Scientific Advisory Board 27
Other Significant Developments 28
Jun 28, 2017: Immunovia Establishes US Headquarters, Including CLIA Reference Laboratory, in Boston 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List Of Tables
List of Tables
Immunovia AB, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immunovia AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immunovia AB, Deals By Therapy Area, 2011 to YTD 2017 8
Immunovia AB, Medical Devices Deals, 2011 to YTD 2017 9
Immunovia AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Immunovia to Enter into Agreement with National Cancer Institute 11
Immunovia Enters into Agreement with University of Liverpool 12
Immunovia Partners with OHSU Knight Cancer Institute 13
Alligator Bioscience Enters Into Licensing Agreement With Immunovia For Scala-11 14
Immunovia Raises USD3.4 Million in Rights Offering of Shares 15
Immunovia Prices Private Placement of Shares for USD22.3 Million 17
Immunovia Plans to Raise Funds in Public Offering of Shares 18
Immunovia Raises USD7 Million in IPO 19
Immunovia AB, Key Competitors 20
Immunovia AB, Key Employees 21
Immunovia AB, Subsidiaries 22
List Of Figures
List of Figures
Immunovia AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immunovia AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Immunovia AB, Medical Devices Deals, 2011 to YTD 2017 9
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter